Pep2m

Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression^{[1][2][3][4][5]}. In Vitro:Pep2m reduces EPSC amplitude and blocks LTD in CA1 pyramidal cells of hippocampal slices by reducing the number of functional AMPARs^[1].

Pep2m reduces the current response to locally applied AMPA in cultured hippocampal neurons^[2].

Pep2m reduces the frequency of recorded AMPA-miniature excitatory postsynaptic currents (mEPSCs) in the presence of tetrodotoxin (TTX)^[2].

Pep2m reduces the surface expression of AMPA receptors containing AMPA-type glutamate receptors (GluR2), but does not reduce the surface expression of NMDA receptors and the ingrowth aggregation of AMPA receptors^[2].

Pep2m does not affect basal synaptic transmission and low-frequency stimulation (LFS)-induced LTD in young GluA2 KO mice, and does not affect basal synaptic transmission but restores LFS-induced LTD in mature GluA2 KO mice^[3].

Pep2m reduces AMPA-induced radiolabeled norepinephrine ([³H]NA) but not AMPA-induced radiolabeled acetylcholine ([³H]Ach) release^[5]. In Vivo:Pep2m (1 μL of 450 nM, ICV, once) impairs learning rate and long-term memory expression in male C57B6J mice^[4].